UroGen Pharma (URGN) Total Liabilities (2016 - 2026)
UroGen Pharma's (URGN) quarterly Total Liabilities came in at $377.9 million in Q1 2026, up 28.52% YoY from $294.1 million in Q1 2025, and up 23.54% on a QoQ basis from $305.9 million in Q4 2025.
UroGen Pharma (URGN) Total Liabilities (2016 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 11 years of Total Liabilities data on file, last reported at $377.9 million in Q1 2026.
- Quarterly Total Liabilities rose 28.52% year-over-year to $377.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $377.9 million (up 28.52% YoY) and the FY2025 annual result came in at $305.9 million, up 3.88% from the prior year.
- Total Liabilities rose to $377.9 million in Q1 2026, from $305.9 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $377.9 million in Q1 2026 to a low of $182.8 million in Q1 2022.
- A 5-year average of $257.2 million and a median of $243.5 million in 2023 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities surged 773.63% — and 2025, when it grew 3.88%.
- Tracing URGN's Total Liabilities over 5 years: stood at $225.0 million in 2022, then advanced by 8.24% to $243.5 million in 2023, then gained by 20.94% to $294.5 million in 2024, then rose by 3.88% to $305.9 million in 2025, then grew by 23.54% to $377.9 million in 2026.
- The last three Total Liabilities figures came in at $377.9 million (Q1 2026), $305.9 million (Q4 2025), and $300.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | 384.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 384.99 Mn |
| Mar 31, 2026 | 377.94 Mn |
| Dec 31, 2025 | 305.93 Mn |
| Sep 30, 2025 | 300.45 Mn |
| Jun 30, 2025 | 302.09 Mn |
| Mar 31, 2025 | 294.08 Mn |
| Dec 31, 2024 | 294.51 Mn |
| Sep 30, 2024 | 276.43 Mn |
| Jun 30, 2024 | 251.54 Mn |
| Mar 31, 2024 | 240.71 Mn |
| Dec 31, 2023 | 243.52 Mn |
| Sep 30, 2023 | 235.63 Mn |
| Jun 30, 2023 | 233.80 Mn |
| Mar 31, 2023 | 229.51 Mn |
| Dec 31, 2022 | 224.98 Mn |
| Sep 30, 2022 | 191.76 Mn |
| Jun 30, 2022 | 187.05 Mn |
| Mar 31, 2022 | 182.79 Mn |
| Dec 31, 2021 | 111.33 Mn |
| Sep 30, 2021 | 103.07 Mn |